Conclusions
TNBC, EGFR-expressing malignancies, head and neck cancer
COLORECTAL CANCER, HEAD AND NECK CANCER
In summary, this trial investigated the role of anti-EGFR-ILs-dox in TNBC. The main limitation of this study is its one-armed design. We addressed this by using previous data from the ATHENA trial as a comparator, which is, however, a historical data set. Although safe, based on the negative efficacy results of this trial, anti-EGFR-ILs-dox should not be further developed for TNBC. Its potential role in other EGFR-expressing malignancies, such as head and neck cancer and colorectal cancer, will need further assessment in other clinical trials.